Next review date: TBC

This guideline offers evidence-based advice on the care of men referred to secondary care with suspected or diagnosed prostate cancer, including follow-up in primary care for men with diagnosed prostate cancer.

It was previously called prostate cancer: diagnosis and treatment.

This guideline updates and replaces prostate cancer: diagnosis and treatment (CG58) and denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (TA194). 

  • National Institute for Health and Care Excellence (NICE) accreditation logo